Ephion Health is a digital health company delivering a hardware-agnostic AI platform that transforms mobility data into clinically validated digital biomarkers. We generate objective, sensitive measures of functional capacity in people with mobility-impairing diseases, enabling pharma companies to de-risk drug development and providing clinicians with precise, data-driven decision-support tools.
Evimatic® is the first personal scientific evidence analyzer, designed to automate the analysis of all available evidence and generate new, updated knowledge accessible whenever and wherever required. Powered by transparent and user-customizable AI reasoning, the platform is currently implemented to evaluate the efficacy, safety, and benefit-risk ratio of both pharmacological and non-pharmacological treatments for ADHD. Evimatic target users and value proposition are:
Clinicians: Healthcare professionals treating patients with ADHD who require detailed information on all available treatments, reflecting the full clinical diversity of the disorder.
Guideline and Protocol Developers: Teams requiring rapid evidence synthesis with transparent and replicable reasoning to generate recommendations that update automatically.
Researchers: ADHD treatment investigators needing access to raw data, API integration, and total transparency through configurable heuristics and auditable reasoning.
Educators: Undergraduate and postgraduate faculty seeking an interactive tool for teaching evidence analysis and clinical therapeutic reasoning.
Xavier Castells Cervelló
Partnership Goal
Evimatic® is seeking partners in the mental health or ADHD space. We look for organizations developing, marketing or distributing diagnostic and monitoring tools that wish to enhance their value proposition with our transparent and customizable evidence-analysis AI technology:
Digital Health Providers (ADHD Diagnosis, Screening and ADHD symptom severity tracking): We are looking to collaborate with companies that market digital technologies for ADHD diagnosis or screening. Our goal is to create a comprehensive solution by integrating Evimatic’s advanced treatment analysis, providing clinicians and patients with a seamless end-to-end solution—from initial detection to evidence-based therapeutic selection.
Technology Distributors: We are seeking experienced distributors of technological solutions with a specialized interest in the ADHD, neurodevelopmental disorders, and child and adolescent mental health markets. We offer a unique, high-value tool that addresses the critical gap in ADHD therapeutics knowledge management, designed to be a cornerstone in the portfolio of distributors serving specialized clinics, hospitals, and educational institutions.
By partnering with Evimatic, organizations can leverage our transparent AI reasoning to provide comprehensive ADHD therapeutics knowledge management, ensuring that professionals have immediate access to the most recent and relevant scientific information.
We accelerate the discovery and development of life-changing medicines by focusing on scientific excellence coupled with deep disease understanding and proprietary next-gen technology platforms.
fetaLife Technologies is a medtech spin-off of the SJD Barcelona Children's Hospital, the Hospital Clínic and the Unniversitat de Barcelona, dedicated to the development of a Fetal Liquid Incubator, a disruptive solution for extremely premature babies (22–26 weeks of gestation).
At Flavii, we are committed to making epigenetic treatments available for patients suffering from brain disorders. We strongly believe that by harnessing the power of epigenetic modulation, we can develop transformative therapies that meaningfully improve the lives of patients and their families, while addressing high unmet medical needs in neurology.
The partnership goal of Flavii in early preclinical stage is to de-risk the program through collaborations with CROs, CDMOs, and technology partners supporting CMC and preclinical validation. As the program advances toward IND and Phase I, the focus shifts to generating external credibility and value-adding signals. The ultimate objective is to reach a key inflection point (Phase I or IIa) to out-license the asset to a pharmaceutical partner. This strategy maximizes valuation while minimizing dilution and development risk.
Franklyn Health is a full-service CRO dedicated to supporting clinical studies for medical device and in vitro diagnostics innovators. We are headquartered in the UK, with an office in Barcelona (ES) and Aarhus (DK). We support studies in the EU and the UK, but also have broad experience in the US and Australia/New Zealand. We provide clinical study support and can support regulatory strategy as well.
Connect with medical device and in vitro diagnostic innovators to learn about the technology they are developing and explore where we can support their clinical evidence generation to bring their technology to market in the most efficient way.
Somos una empresa de selección de personal especializada en los sectores sanitario y biotecnológico. Nos enfocamos en la incorporación de profesionales sanitarios altamente cualificados. Combinamos una sólida experiencia en el ámbito de la salud con un profundo conocimiento en reclutamiento sanitario, lo que nos permite garantizar incorporaciones fiables, eficientes y duraderas.
